{"id":31402,"date":"2021-07-13T09:38:12","date_gmt":"2021-07-13T08:38:12","guid":{"rendered":"https:\/\/wames.org.uk\/cms-english\/?p=31402"},"modified":"2021-08-18T20:29:40","modified_gmt":"2021-08-18T19:29:40","slug":"tolerability-efficacy-of-s-c-igg-self-treatment-in-me-cfs-patients-with-igg-igg-subclass-deficiency","status":"publish","type":"post","link":"https:\/\/wames.org.uk\/cms-english\/tolerability-efficacy-of-s-c-igg-self-treatment-in-me-cfs-patients-with-igg-igg-subclass-deficiency\/","title":{"rendered":"Research: Tolerability & efficacy of s.c. IgG self-treatment in ME\/CFS patients with IgG\/IgG subclass deficiency"},"content":{"rendered":"

Tolerability and efficacy of s.c. IgG self-treatment in ME\/CFS patients with IgG\/IgG subclass deficiency: a proof-of-concept study<\/a>, by Carmen Scheibenbogen, Franziska Sotzny, Jelka Hartwig, Sandra Bauer, Helma Freitag, Kirsten Wittke, Wolfram Doehner, Nadja Scherbakov, Madlen Loebel, Patricia Grabowski in<\/span> J Clin Med<\/em>. 2021 May 29;10(11):2420 [doi: 10.3390\/jcm10112420]<\/h3>\n

 <\/p>\n

Research abstract:<\/strong><\/h3>\n

Background: <\/strong><\/p>\n

Chronic fatigue syndrome (ME\/CFS) is a complex disease frequently triggered by infections. IgG<\/a> substitution may have therapeutic effect both by ameliorating susceptibility to infections and due to immunomodulatory effects.<\/p>\n

Methods: <\/strong><\/p>\n

\"\"We conducted a proof of concept open trial with s.c.<\/a> IgG in\u00a017 ME\/CFS patients suffering from recurrent infections and mild IgG or IgG subclass deficiency to assess tolerability and efficacy. Patients received s.c. IgG therapy of 0.8 g\/kg\/month for 12 months with an initial 2 months dose escalation phase of 0.2 g and 0.4 g\/kg\/month.<\/p>\n

Results: <\/strong><\/p>\n

Primary outcome was improvement of fatigue assessed by Chalder Fatigue Scale (CFQ; decrease \u2265 6 points) and of physical functioning assessed by SF-36 (increase \u2265 25 points) at month 12. Of\u00a012 patients receiving treatment per protocol 5 had a clinical response at month 12. Two additional patients had an improvement according to this definition at months 6 and 9. In four patients treatment was ceased due to adverse events and in one patient due to disease worsening. We identified LDH<\/a> and soluble IL-2 receptor<\/a> as potential biomarker for response.<\/p>\n

Conclusion: <\/strong><\/p>\n

Our data indicate that self-administered s.c. IgG treatment is feasible and led to clinical improvement in a subset of ME\/CFS patients.<\/p>\n

Limitations<\/strong><\/h3>\n

Taken together, our study has several limitations, including a small patient number and a lack of a control arm. The strength of this study is to show the feasibility of a dose escalation s.c. IgG home treatment in ME\/CFS patients. Furthermore, it provides first evidence for efficacy of an intermediate dose s.c. IgG treatment and potential biomarkers for response. This warrants an RCT study.<\/p>\n","protected":false},"excerpt":{"rendered":"

Tolerability and efficacy of s.c. IgG self-treatment in ME\/CFS patients with IgG\/IgG subclass deficiency: a proof-of-concept study, by Carmen Scheibenbogen, Franziska Sotzny, Jelka Hartwig, Sandra Bauer, Helma Freitag, Kirsten Wittke, Wolfram Doehner, Nadja Scherbakov, Madlen Loebel, Patricia Grabowski in J … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[4267,6120,5771,5640,6723,6904,5729,4268,6905,4575,6906,5725],"class_list":["post-31402","post","type-post","status-publish","format-standard","hentry","category-news","tag-carmen-scheibenbogen","tag-helma-freitag","tag-immunoglobulin-replacement-therapy","tag-jelka-hartwig","tag-kirsten-wittke","tag-madlen-loebel","tag-nadja-scherbakov","tag-patricia-grabowski","tag-s-c-igg","tag-sandra-bauer","tag-subcutaneous-injection","tag-wolfram-doehner"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p5qkYK-8au","_links":{"self":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/31402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/comments?post=31402"}],"version-history":[{"count":4,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/31402\/revisions"}],"predecessor-version":[{"id":32469,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/31402\/revisions\/32469"}],"wp:attachment":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/media?parent=31402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/categories?post=31402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/tags?post=31402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}